

***Bifidobacteria* probiotic: prevention and treatment of obesity.**

Priyanka Dhyani*

Department of Microbiology, Harvard University, Cambridge, United States

Abstract

Obesity has become a severe public health problem in recent decades, impacting both children and adults. The most prevalent cause is an imbalance in energy intake and expenditure. Obesity is linked to changes in the function and makeup of the gut microbiota, according to scientific research. The gut microbiome of healthy persons differs from that of lean people. As a result, the gut microbiota can be adjusted to achieve optimum health. Obesity is linked to alterations in the Bacteroidetes and Firmicutes bacterial divisions. Firmicutes are a sign of obesity, but bifido is a sign of a healthy weight speciality. As a result, the gut microbiota, an important pathophysiological component, plays a key role in obesity development. Changing the gut flora has the ability to increase or reduce body weight and BMI. Probiotics have been found to alter the makeup of the gut microbiota, increase gut integrity, and reverse obesity-related microbial shifts. As a result, probiotics have been proposed as a potential approach for preventing and treating obesity. The greatest answer to the problem is to control the diet and lifestyle factors that promote obesity development. The goal of this study is to examine the huge amount of evidence available on the composition, function, and alternations of the gut microbiota in obesity, *Bifidobacterium's* antiobesity benefits, probiotics for treating obesity, and the field's future prospects.

Keywords: Gut Microbiota, *Bifidobacteria*, *Lactobacillus*, Probiotic, Obesity, Visceral Fat.

Introduction

Obesity is connected with a greatly increased mortality rate and is a risk factor for numerous diseases, including diabetes, stroke, and cancer, and is defined as a BMI of more than 30 kg/m² and a huge expansion of fat (visceral fat) [1]. Obesity is on the rise among adults, adolescents, and children, and has more than doubled since 1960, when it was first recognised as a global epidemic. In the Global Obesity Index, India is ranked third [2]. In 2014, nearly 1.9 billion persons over the age of 18 were overweight, and by 2020, 39 million children under the age of five will be overweight or obese [3]. Despite major efforts over the last decade to reduce the prevalence of obesity, progress in understanding the aetiology and numerous processes regulating its development, which could lead to the development of effective therapeutic options for treatment, has been slow. New research suggests that the gut microbiota is a significant contributor to obesity, given the wide range of variables and their intricate interactions [4]. The gut microbiota is the collection of microorganisms found in the Gastrointestinal (GI) tract, beginning in the mouth cavity and growing in density as it travels down the small and large intestine. The gut microbiota has been identified as a potential predictor of obesity in recent human and animal research [5]. Several probable pathways by which the gut microbiota contributes to and/or influences obesity have been outlined by a significant body of evidence. Although much remains

unknown and debated, there is a general consensus that the gut microbiota plays a role in obesity *via* dietary carbohydrate fermentation, lipogenesis, excess energy storage, and a variety of other pathways involving a wide range of metabolites, hormones, and neurotransmitters, some of which are known to regulate food intake and energy balance [6]. Furthermore, there is compelling evidence that the makeup and diversity of the gut microbiota in obese animals and humans differ from their lean counterparts [7]. Obesity is linked to alterations in the Bacteroidetes and Firmicutes bacterial divisions, respectively. When obese persons are compared to lean people, this proportion drops and increases with weight loss in two sorts. These results show that restoring the compositional profile and richness of the gut microbiota could help people lose weight [8]. The use of probiotics is one method of achieving this. By changing the number and functions of numerous intestinal micro biotas, probiotics can help to prevent, treat, and manage obesity.

Literature Review

Gut microbiota

The microbiota in our gut determines our health. The human intestine contains 10-100 trillion microbes. Firmicutes (60-80%) and Bacteroidetes (20-30%) are the most common phyla and genera in human gut microbiota [9]. The gut microbiota, which digests plant carbohydrates and milk products, increases

*Correspondence to: Dhyani P. Department of Microbiology, Harvard University, Cambridge, United States, E-mail: priyankadhyani60@gmail.com

Received: 06-Sep-2022, Manuscript No. AAFMY-22-56932; Editor assigned: 07-Sep-2022, PreQC No. AAFMY-22-56932(PQ); Reviewed: 21-Sep-2022, QC No AAFMY-22-56932;

Revised: 23-Sep-2022, AAFMY-22-56932(R); Published: 30-Sep-2022, DOI:10.35841/aafmy-6.5.125

the host's metabolic capacity (glycans). It contains vitamins B2, B12, K, and folic acid. Recent evidence, primarily from animal model studies, suggests that gut microbiota influence nutrient acquisition and energy regulation [10]. The stomach Microbiota contributes to energy homeostasis by extracting energy from food *via* fermentation processes and the formation of Short-Chain Fatty Acids (SCFAs). Furthermore, the microbiota modulates and inhibits the release of Fasting-Induced Adipose Factor (FIAP), an inhibitor of Lipoprotein Lipase (LPL) activity, resulting in triglyceride storage in adipose tissue and the liver [11]. Gut dysbiosis is linked to a number of pathologic conditions that affect the gastrointestinal tract (diarrhoea, irritable bowel syndrome), the immune system (allergy, multiple sclerosis, type 1 diabetes, rheumatoid arthritis, inflammatory bowel syndrome), the central nervous system (Alzheimer's disease, autism), and the host's energy metabolism (obesity, type 2 diabetes, atherosclerosis). The relationship between the two dominant phyla, expressed as the Firmicutes/Bacteroidetes ratio, has been linked to a number of pathological conditions [12]. Accordingly, the gut microbiota is emerging as a promising target for the nutritional or therapeutic prevention and management of these diseases.

Gut microbiota of obese vs. lean individual

The human gut microbiota is made up of trillions of bacteria that fall into two major bacterial groups: firmicutes and bacteroidetes. These two phyla are involved in the development of obesity and microbial dysbiosis. Several animal and human studies have revealed differences in the composition of gut microbiota and energy metabolism in obese and lean populations. When the gut microbiota of obese and lean people was compared, obesity was found to have higher proportions of firmicutes and lower proportions of bacteroidetes [13]. Obese subjects had a lower proportion of bacteria than people with a normal Body Mass Index (BMI). A subsequent large metagenomics study resolving the gut microbiome in obese and lean twins discovered lower bacterial diversity and bacteroidetes proportion in obese people than in lean people [14]. As a result, the relative abundance of firmicutes to bacteroidetes (i.e., the F/B ratio) appeared to be a biomarker of obesity susceptibility [15]. Several animal and human studies have revealed differences in the composition of gut microbiota and energy metabolism in obese and lean populations. In a study examining the relationship between gut microbiota composition and body fat loss, 12 obese adult men and women randomly assigned to either a low-fat or low carbohydrate diet for one year had fewer bacteria and a higher ratio of firmicutes/bacteroidetes when compared to lean, normal-weight controls. However, in those who lost weight successfully and sustainably, the ratio returned to normal [16]. Based on these findings, it could be concluded that the F/B ratio is a marker of obesity and that efforts to restore this ratio to normal could aid in the prevention and treatment of obesity [17].

Some studies were unable to demonstrate this association, while others discovered the opposite trend. Evidence of a link between the prevalence of a particular bacterial genus and obesity or leanness does not explain whether the

microorganism is truly the cause of obesity or normal weight [18]. The genera *Bifidobacterium*, *Erwinia*, *Alistipes*, and *Oscillospira*, on the other hand, were thought to be protective because they were found to be more abundant in subjects of normal weight than in obese subjects [19].

Antiobesity effects of *Bifidobacteria*

There are trillions of bacteria on and inside your body, and they are critical to your health. *Bifidobacteria* is one of the most important types. *Bifidobacteria* are gram-positive, non-motile y-shaped bacteria that are extremely beneficial to your health. Low *Bifidobacteria* counts have been linked to a variety of diseases, and their supplements may aid in the treatment of certain symptoms [20]. Nearly 50 species of these beneficial bacteria have been discovered by researchers, each of which is thought to have unique functions and health benefits. Despite their importance, they account for less than 10% of the bacteria in the adult gut microbiome. This bacteria's main function in humans is to digest fibre and other complex carbohydrates that your body cannot digest on its own. Fiber has been shown to aid in weight loss. *Bifidobacteria* may help reduce the risk of these diseases by digesting fibre [21]. This is due to the fact that when beneficial bacteria digest fibre, they produce important chemicals known as Short-Chain Fatty Acids (SCFAs). These compounds play a variety of important roles in gut health and may also aid in hunger control [22].

Experimental studies supporting the antiobesity effect

There was an overall favourable effect when *Bifidobacteria lactis* HN019 was given to patients with metabolic syndrome, including a reduction in adiposity [23]. Higher levels of *B. animalis*, *L. paracasei*, or *L. plantum* were linked to normal weight, implying a link between these species and lean and obese people [24]. Hyang Mi An discovered that a high-fat diet fed group gained considerable weight after 5 weeks, and that providing *Bifidobacteria* to that group reduced body weight gain and fat weight gain [25]. Body weight and epididymal fat accumulation were reduced in high-fat diet mice fed with *Bifidobacterium breve* B-3 for 8 weeks. It improved total cholesterol, fasting glucose, and insulin levels in the blood, showing that the strain is helpful in lowering the risk of obesity [26]. When given to obese mice on a High-Fat Diet (HFD), *Bifidobacteria longum* counteracted the effects of obesity by lowering their BMI [27].

Use of *Bifidobacteria* in probiotic to reduce visceral fat

Elie Metchnikoff, a 28 years employee at the prestigious Pasteur Institute in Paris, was the first to suggest that lactic acid bacteria were advantageous to the gut microbiota. He was the one who initially discovered a probiotic strain. Probiotics are live microorganisms that are advertised with the premise that when taken, they improve or restore gut flora, hence improving or restoring health [28]. In obesity, gut flora has a modulatory role. As a result, improving the status of obesity by regulating the gut by dietary or other measures, such as probiotics, is possible [29]. Probiotics can provide

helpful microorganisms to your body directly, which has its own set of health benefits. The most often utilized probiotics are *Bifidobacterium* and *Lactobacillus* species. *Bifidobacteria* have been added as active ingredients in several functional meals due to their putative health-promoting characteristics [30]. The flora of the gut and visceral fat has a link. The proportion of *Bifidobacteria* in the intestine is found to be adversely correlated with visceral fat [31]. It means that someone with a lot of *Bifidobacteria* has a healthy weight and someone with less no. of *Bifidobacteria* has obesity. That is, if your body contains a lot of *Bifidobacteria*, it can aid in the loss of visceral fat. This information is about a product that prevents the production of visceral fat by increasing the relative number of *Bifidobacteria* in the intestines. Probiotics, particularly *Bifidobacteria*, will raise the ratio of it in a person's body, resulting in decreased visceral fat and the prevention of obesity [32]. As a result, creating a probiotic product that may enhance the amount of probiotics in the body can directly reduce visceral fat and hence prevent the health risks connected with it. This can reduce the need for treatment expenditures as well as the danger of bariatric surgery [33].

Human probiotic studies

Probiotic strains from the genera *Bifidobacterium* and *Lactobacillus* have been studied extensively for their effects on weight gain and loss. Positive results have been recorded in the majority of them, in both adults and children [34]. In a 12 weeks double-blind, randomised, placebo-controlled experiment, Kadooka gave fermented milk containing *Lactobacillus gasseri* LG2055 to persons with a higher BMI and abdominal visceral fat regions. The visceral and subcutaneous fat regions of the subjects who received the probiotic both dropped by 4.6 percent and 3.3 percent, respectively [35]. Probiotic use was related with a significant reduction in all examined parameters, according to a total of 8099 studies identified, 21 randomised trials (i.e. body weight and fat mass). The amount of probiotic dose and its impact, on the other hand, are still unknown [36]. For example, a low dose of probiotic resulted in a lower BMI decrease but a bigger reduction in visceral fat, while a longer period of probiotic treatment with a low dose resulted in a reduction in both BMI and visceral fat. These investigations indicated that probiotics are an important therapy for treating obesity because they modulate the gut microbiome [37].

Probiotic limitations in obesity

The lack of human studies, heterogeneity among the studied subgroups in terms of age, gender, and lifestyle, and the use of different agents with potential therapeutic effects in different formulations, doses, ratios, and pharmacodynamics/pharmacokinetics are some of the major limitations of probiotics in obesity research [38]. With the exception of the

Use of probiotics in immunocompromised patients, probiotic supplementation has not been linked to major side effects in immune-competent persons.

Discussion

Increased research in the last decade targeted at defining probiotic processes and determining clinical efficacy indicate

to a bright future for *Bifidobacteria* in the treatment of obesity and a number of other pathological disorders. Probiotic dietary supplements aid in the fermentation of dairy and non-dairy foods, which is beneficial not only in the treatment of obesity but also cancer and diabetes [39]. The application, however, is still limited. Future research should focus on learning more about how changes in the gut microbiota cause obesity or how obesity affects microbiome makeup. This link, as well as the minute interactions between human and gut flora, could be the key to meaningful clinical translation [40].

The development of more customised and targeted probiotic medicines will be aided by a better understanding of this intricate interaction. Furthermore, the majority of research in this rapidly evolving field has focused on *Lactobacillus* and *Bifidobacterium* strains, necessitating the identification of new bacterial possibilities as well as their possible mechanistic effects on obesity [41]. Clinical cohorts have traditionally had small sample numbers and have concentrated on short-term physical characteristics or inflammatory markers,

Making long-term follow-up research in the future particularly desirable. Despite the fact that probiotics are considered safe for oral intake, there are currently no standard standards for probiotic administration in humans [42]. The effects of probiotics may vary based on the individual and the type of probiotic-containing diet. As a result, further research is needed to better understand the intricate interplay between intestinal and ingested microbiota [43].

Conclusion

Obesity has far-reaching and burdensome implications, not just in terms of individual health outcomes, but also in terms of having a huge financial impact on society as a whole. Because of the negative impacts and obese people's inability to maintain long-term weight loss, clinical treatment for obesity remains difficult. Although bariatric surgery is helpful in lowering weight, it is invasive and hazardous, and it necessitates a significant amount of effort in adopting a new lifestyle. These facts compel scientists and clinicians to devise fresh techniques to manage this ever-increasing problem, and probiotics, which are generally regarded safe for human health, have showed some promise among the prospective remedies. Evidence is mounting suggesting the gut microbiota is important in maintaining energy homeostasis and, as a result, in the development and progression of obesity and related metabolic diseases. In this context, a vast number of researches in both animals and humans have demonstrated that addressing the gut microbiota may be a useful method for preventing and managing obesity. By changing the makeup of the gut microbiota and restoring the physiological bacterial flora, probiotics can provide significant health advantages. Despite the fact that a rising number of research have pointed to probiotics' therapeutic effects on obesity, there is still a scarcity of evidence in this field. The most significant effects of probiotics on host metabolism and obesity have been documented mostly for *Bifidobacterium/Lactobacillus* strains in human research. Bacterial strains such as *B. longum* SPM 1205, *B. longum* SPM 1207, and *B. pseudocatenulatum* SPM 1204 have anti-obesity properties. Because *Bifidobacterium*

has a negative link with visceral fat, probiotics pills containing these bacterial strains can help people lose weight. More prospective bacterial candidates, as well as the mechanisms driving their anti-obesity benefits, should be found. Future study should concentrate on knowing more about how alterations in the gut microbiota create obesity or how obesity impacts microbiome makeup, as well as the complex interplay between intestinal and ingested bacteria.

References

- Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. *Obes Res.* 2002;10(S12):97S-104S.
- Kalra S, Unnikrishnan AG. Obesity in India: The weight of the nation. *JMNN* 2012;1(1):37.
- Lim HJ, Xue H, Wang Y (2020) Global Trends in Obesity. In: Meiselman H. (eds) *Handbook of Eating and Drinking*. Springer, Cham, 1217-1235
- Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. *Lancet Diabetes Endocrinol.* 2015;3(3):207-15.
- Korpela K, Flint HJ, Johnstone AM, et al. Gut microbiota signatures predict host and microbiota responses to dietary interventions in obese individuals. *PloS one.* 2014;9(3):e90702.
- Blaut M. Gut microbiota and energy balance: role in obesity. *Proc Nutr Soc.* 2015;74(3):227-34.
- Kootte RS, Vrieze A, Holleman F, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. *Diabetes Obes Metab.* 2012;14(2):112-20.
- Parnell JA, Reimer RA. Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR: LA-cp rats. *BJN.* 2012;107(4):601-13.
- Pitocco D, Di Leo M, Tartaglione L, et al. The role of gut microbiota in mediating obesity and diabetes mellitus. *Eur Rev Med Pharmacol Sci.* 2020;24(3):1548-62.
- Kimura I, Ozawa K, Inoue D, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. *Nat Commun.* 2013;4(1):1-2.
- Qiao Y, Sun J, Xia S, et al. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. *Food Funct.* 2014;5(6):1241-9.
- Yang T, Santisteban MM, Rodriguez V, et al. Gut dysbiosis is linked to hypertension. *HT.* 2015;65(6):1331-40.
- Indiani CM, Rizzardi KF, Castelo PM, et al. Childhood obesity and firmicutes/bacteroidetes ratio in the gut microbiota: a systematic review. *Child Obes.* 2018;14(8):501-9.
- John GK, Mullin GE. The gut microbiome and obesity. *Curr Oncol Rep.* 2016;18(7):1-7.
- Magne F, Gotteland M, Gauthier L, et al. The firmicutes/bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients?. *Nutrients.* 2020;12(5):1474.
- Grembi JA, Nguyen LH, Haggerty TD, et al. Gut microbiota plasticity is correlated with sustained weight loss on a low-carb or low-fat dietary intervention. *Sci Rep.* 2020;10(1):1-4.
- Naveena N, Somasundaram J. Role of probiotics in prevention of obesity. *EJMCM.* 2020;7(01):2020.
- Marasco G, Ciota GG, Rossini B, et al. Probiotics, prebiotics and other dietary supplements for gut microbiota modulation in celiac disease patients. *Nutrients.* 2020;12(9):2674.
- Hou L, Yang Y, Sun B, et al. Dietary Fiber, Gut Microbiota, Short-Chain Fatty Acids, and Host Metabolism. *Am J Life Sci.* 2021;9(6):162-72.
- Nogal A, Valdes AM, Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. *Gut microbes.* 2021;13(1):1897212.
- Bernini LJ, Simão AN, Alfieri DF, et al. Beneficial effects of *Bifidobacterium lactis* on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. *Nutrition.* 2016;32(6):716-9.
- Million M, Maraninchi M, Henry M, et al. Obesity-associated gut microbiota is enriched in *Lactobacillus reuteri* and depleted in *Bifidobacterium animalis* and *Methanobrevibacter smithii*. *IJO.* 2012;36(6):817-25.
- An HM, Park SY, Lee DK, et al. Antiobesity and lipid-lowering effects of *Bifidobacterium* spp. in high fat diet-induced obese rats. *Lipids Health Dis.* 2011;10(1):1-8.
- Kondo S, Xiao JZ, Satoh T, et al. Antiobesity effects of *Bifidobacterium breve* strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. *Biosci Biotechnol Biochem.* 2010;74(8):1656-61.
- Schellekens H, Torres-Fuentes C, van de Wouw M, et al. *Bifidobacterium longum* counters the effects of obesity: Partial successful translation from rodent to human. *EBioMedicine.* 2021;63:103176.
- Sanders ME, Merenstein DJ, Reid G, et al. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nat Rev Gastroenterol Hepatol.* 2019;16(10):605-16.
- He M, Shi B. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. *Cell Biosci.* 2017;7(1):1-4.
- Lordan C, Thapa D, Ross RP, et al. Potential for enriching next-generation health-promoting gut bacteria through prebiotics and other dietary components. *Gut microbes.* 2020;11(1):1-20.

Citation: Priyanka Dhyani. *Bifidobacteria probiotic: prevention and treatment of obesity. J Food Microbiol.* 2022;6(5):125

29. Chen J, Wang R, Li XF, et al. Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. *BJN*. 2012;107(10):1429-34.
30. Abenavoli L, Scarpellini E, Colica C, et al. Gut microbiota and obesity: a role for probiotics. *Nutrients*. 2019;11(11):2690.
31. Kadooka Y, Sato M, Imaizumi K, et al. Regulation of abdominal adiposity by probiotics (*Lactobacillus gasseri* SBT2055) in adults with obese tendencies in a randomized controlled trial. *Eur J Clin Nutr*. 2010;64(6):636-43.
32. Barathikannan K, Chelliah R, Rubab M, et al. Gut microbiome modulation based on probiotic application for anti-obesity: A review on efficacy and validation. *Microorganisms*. 2019;7(10):456.
33. Vallianou N, Stratigou T, Christodoulatos GS, et al. Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives. *Curr Obes Rep*. 2020;9(3):179-92.
34. Kothari D, Patel S, Kim SK. Probiotic supplements might not be universally-effective and safe: A review. *Biomed Pharmacother*. 2019;111:537-47.
35. Zepeda-Hernández A, Garcia-Amezquita LE, Requena T, et al. Probiotics, prebiotics, and synbiotics added to dairy products: Uses and applications to manage type 2 diabetes. *Int Food Res*. 2021;142:110208.
36. Cunningham M, Azcarate-Peril MA, Barnard A, et al. Shaping the future of probiotics and prebiotics. *Trends in microbiology*. 2021;29(8):667-85.
37. Suez J, Zmora N, Segal E, et al. The pros, cons, and many unknowns of probiotics. *Nat. Med*. 2019;25(5):716-29.
38. Sharma M, Wasan A, Sharma RK. Recent developments in probiotics: An emphasis on *Bifidobacterium*. *Food Bioscience*. 2021;41:100993.
39. Rosenbaum M, Knight R, Leibel RL. The gut microbiota in human energy homeostasis and obesity. *Trends Endocrinol Metab*. 2015;26(9):493-501.
40. Cuevas-Sierra A, Ramos-Lopez O, Riezu-Boj JI, et al. Diet, gut microbiota, and obesity: links with host genetics and epigenetics and potential applications. *Adv Nutr*. 2019;10:S17-30.
41. DiBaise JK, Zhang H, Crowell MD, et al. Gut microbiota and its possible relationship with obesity. In *Mayo clinic proceedings*. 2008;83(4):460-469.
42. Kang Y, Cai Y. The development of probiotics therapy to obesity: a therapy that has gained considerable momentum. *Hormones*. 2018;17(2):141-51.
43. Nova E, Pérez de Heredia F, Gómez-Martinez S, et al. The role of probiotics on the microbiota: effect on obesity. *Nutr Clin Pract*. 2016;31(3):387-400.